Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-
Clinical Trials
Related News

Geodon for the Treatment of Refractory Social Anxiety Disorder

Phase 2
Completed
Conditions
Social Anxiety Disorder
Interventions
Drug: Ziprasidone
Drug: Sertraline
First Posted Date
2005-09-22
Last Posted Date
2014-10-31
Lead Sponsor
Duke University
Target Recruit Count
51
Registration Number
NCT00215150
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

Geodon (Ziprasidone) for Posttraumatic Stress Disorder

First Posted Date
2005-09-21
Last Posted Date
2006-09-15
Lead Sponsor
Creighton University
Target Recruit Count
80
Registration Number
NCT00208208
Locations
🇺🇸

Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States

Ziprasidone in Children With Autism: A Pilot Study

Phase 2
Completed
Conditions
Autism
Interventions
Drug: Ziprasidone
First Posted Date
2005-09-21
Last Posted Date
2010-06-17
Lead Sponsor
Drexel University College of Medicine
Target Recruit Count
15
Registration Number
NCT00208559
Locations
🇺🇸

Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States

Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness

First Posted Date
2005-09-20
Last Posted Date
2008-03-12
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
20
Registration Number
NCT00199940

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: Ziprasidone
First Posted Date
2005-09-15
Last Posted Date
2021-03-24
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
43
Registration Number
NCT00174447
Locations
🇫🇷

Pfizer Investigational Site, Versailles, France

Energy Homeostasis Under Treatment With Atypical Antipsychotics

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: olanzapine
Drug: Ziprasidone
First Posted Date
2005-09-08
Last Posted Date
2008-09-29
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
40
Registration Number
NCT00148564
Locations
🇩🇪

Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy, Berlin, Germany

Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind Study

Phase 3
Completed
Conditions
Schizophrenia
Psychotic Disorders
First Posted Date
2005-09-05
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
100
Registration Number
NCT00145444
Locations
🇳🇱

Pfizer Investigational Site, Utrecht, Netherlands

Mozart Relapse Study

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-02
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
75
Registration Number
NCT00143351
Locations
🇮🇹

Pfizer Investigational Site, Verona, Italy

Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-08-31
Last Posted Date
2021-03-03
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
344
Registration Number
NCT00139737
Locations
🇮🇹

Pfizer Investigational Site, Viareggio, Italy

IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)

Phase 3
Completed
Conditions
Schizophrenia
First Posted Date
2005-08-29
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
160
Registration Number
NCT00136994
Locations
🇮🇹

Pfizer Investigational Site, Viareggio, Italy

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy